Iain Dukes

Dr. Dukes is a Venture Partner at OrbiMed Advisors. He is also Chairman of Iovance Biotherapeutics (NASQ: IOVA) and serves on the Board of Directors of Themis Biosciences (acquired by Merck & Co), Ikena Oncology, KaNDy Therapeutics (previously as Chairman, acquired by Bayer AG), ReViral Limited, ENYO Pharma and Feldan Therapeutics. He co-founded and is CEO and Chairman of Theseus Pharmaceuticals and CEO of Viriom Inc. He co-founded and is President of Kartos Therapeutics and Telios Pharma. He is also Executive Chairman of Angiex and Chairman of the Loch family of oncology companies, of which six have been formed to date.